OPTIMAS CAPITAL Ltd Has $7.95 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

OPTIMAS CAPITAL Ltd cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 14.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,632 shares of the company’s stock after selling 2,254 shares during the quarter. Eli Lilly and Company accounts for 7.5% of OPTIMAS CAPITAL Ltd’s portfolio, making the stock its 2nd largest holding. OPTIMAS CAPITAL Ltd’s holdings in Eli Lilly and Company were worth $7,946,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of the business. Fairfield Bush & CO. purchased a new stake in shares of Eli Lilly and Company during the first quarter worth $107,000. Roundview Capital LLC raised its holdings in shares of Eli Lilly and Company by 2.6% during the first quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock worth $589,000 after acquiring an additional 53 shares in the last quarter. Merit Financial Group LLC purchased a new stake in shares of Eli Lilly and Company during the first quarter worth $210,000. NewEdge Advisors LLC raised its holdings in shares of Eli Lilly and Company by 9.9% during the first quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock worth $15,193,000 after acquiring an additional 4,774 shares in the last quarter. Finally, Barometer Capital Management Inc. purchased a new stake in shares of Eli Lilly and Company during the first quarter worth $561,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 195,055 shares of company stock valued at $125,254,657. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on LLY. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Truist Financial reissued a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 22nd. BMO Capital Markets increased their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, February 20th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $689.52.

Eli Lilly and Company Trading Down 0.0 %

LLY stock traded down $0.22 during trading on Thursday, hitting $777.96. The company had a trading volume of 3,208,110 shares, compared to its average volume of 3,236,305. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a 50-day moving average price of $730.97 and a 200-day moving average price of $637.01. Eli Lilly and Company has a 12 month low of $334.58 and a 12 month high of $800.78. The stock has a market cap of $739.19 billion, a price-to-earnings ratio of 134.56, a PEG ratio of 1.70 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the previous year, the company posted $2.09 EPS. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. As a group, analysts predict that Eli Lilly and Company will post 12.42 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.